Artisan Partners Limited Partnership raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,709,020 shares of the biopharmaceutical company’s stock after purchasing an additional 11,260 shares during the quarter. Artisan Partners Limited Partnership owned 1.19% of Halozyme Therapeutics worth $28,831,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of HALO. SG Americas Securities LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at $158,000. Element Capital Management LLC purchased a new position in Halozyme Therapeutics in the first quarter valued at about $198,000. Piermont Capital Management Inc. purchased a new position in Halozyme Therapeutics in the first quarter valued at about $206,000. Eaton Vance Management purchased a new position in Halozyme Therapeutics in the first quarter valued at about $235,000. Finally, Trexquant Investment LP bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth about $246,000. Institutional investors own 83.88% of the company’s stock.

Shares of NASDAQ HALO traded down $0.07 during mid-day trading on Friday, hitting $17.14. The company had a trading volume of 675,421 shares, compared to its average volume of 810,908. Halozyme Therapeutics, Inc. has a one year low of $15.66 and a one year high of $21.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.49 and a quick ratio of 3.43. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of 33.21 and a beta of 1.93.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. Halozyme Therapeutics had a return on equity of 38.10% and a net margin of 23.88%. The business had revenue of $35.20 million during the quarter, compared to analysts’ expectations of $31.49 million. sell-side analysts expect that Halozyme Therapeutics, Inc. will post -0.8 EPS for the current year.

Several analysts have recently issued reports on HALO shares. Cantor Fitzgerald began coverage on Halozyme Therapeutics in a research note on Wednesday, August 22nd. They set an “overweight” rating and a $27.00 price target for the company. BMO Capital Markets increased their target price on Halozyme Therapeutics from $19.00 to $21.00 and gave the stock a “market perform” rating in a report on Wednesday, August 8th. ValuEngine raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Wednesday, July 11th. Finally, BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $22.11.

In related news, major shareholder Randal J. Kirk sold 304,321 shares of the business’s stock in a transaction on Friday, June 29th. The shares were sold at an average price of $17.04, for a total value of $5,185,629.84. Following the sale, the insider now owns 3,562,388 shares of the company’s stock, valued at $60,703,091.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Randal J. Kirk sold 53,505 shares of the company’s stock in a transaction on Wednesday, June 27th. The shares were sold at an average price of $17.34, for a total transaction of $927,776.70. Following the sale, the insider now directly owns 3,562,388 shares in the company, valued at approximately $61,771,807.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,278,021 shares of company stock valued at $74,892,770. Company insiders own 16.80% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: How to Profit and Limit Losses With Stop Orders

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.